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ABSTRACT 
Alzheimer’s disease (AD), the most prevalent neurodegenerative disease, is 
characterized in part by disruptions in axonal transport. Axonal transport is a process by 
which motor proteins carry organelles and other cargo made in the neuronal cell body 
along microtubule tracks to distal regions of the axon. The microtubule-associated protein 
(MAP) Tau plays a crucial role in regulating axonal transport, and is implicated in the 
development of AD and other types of dementia collectively known as Tauopathies. Tau 
is a neuronal-specific MAP that has six isoforms alternatively spliced from a single gene. 
These isoforms differ by the presence of zero, one, or two N-terminal acidic inserts and 
three or four C-terminal microtubule binding repeats. Tau is also known to be an 
intrinsically disordered protein that undergoes a dynamic equilibrium between static and 
diffusive states on the microtubule surface. The dynamics of Tau are important in the 
regulation of motor protein mediated axonal transport in neurons. Isoform-specific 
differences in the dynamic behavior of Tau on the microtubule surface, however, are not 
yet fully understood. Diffusive Tau is thought to be stabilized by electrostatic interactions 
between its N- and C-termini while static Tau is proposed to be extended with its C-
terminal repeats contacting the microtubule and the N-terminus projected away from the 
microtubule surface. Thus, the N-terminal inserts may help regulate Tau’s dynamic 
behavior and function during axonal transport. In this study, the dynamics of two 
different isoforms of Tau, both with three-microtubule binding repeats but a different 
number of N-terminal acidic inserts, were assessed using single molecule imaging 
techniques and novel data analysis methods. 
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This literature review will address from global to the molecular the role of the protein 
Tau in the developed adult brain. The work will begin with a look at the gross features of 
Alzheimer’s disease (AD), some of the known pathological features of AD, and then look 
at proposed molecular causes. One of these proposed molecules involved in AD is the 
protein Tau. The literature review will therefore look at what is known about the structure 
and function of Tau and its known roles in the neurons. One of these is Tau’s influence 
on axonal transport and how that process is disrupted in AD. The review will then 
introduce how Tau’s role in axonal transport is related to its dynamics behavior on the 
microtubule surface. The current understanding is that Tau binds to microtubules in both 
diffusive and static state but little is currently know about differences in dynamic 
behavior among different isoforms of Tau. This study examines the differences in 
dynamics of two Tau isoforms, 3RS and 3RL. In addition, this research will look at 
previous work and limitations of the previous data analysis methods used. The current 
research will introduce a novel data analysis method designed to eliminate subjectivity 
and be more sensitive to short time-scale events. Overall, the literature review will look at 
the pathological features in AD to the physiological processes. This will highlight the 
need to better understand the Tau proteins function and its role in neurodegeneration.  
Alzheimer’s disease is a devastating type of neurodegeneration. 
Alzheimer's disease (AD) is one of the most common types of dementia affecting 
approximately 5.4 million people in the United States1, yet an estimated half of cases go 
undiagnosed2. Since a decrease in cognitive function is normal with aging, distinguishing 
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the transition from normal cognitive decline to mild cognitive impairment (MCI) to AD 
must occur with coordination by the patient, caregivers, and health care providers. 
Patients are often seen in clinics or elsewhere where cognitive decline is a secondary or 
tertiary concern3. Health care providers must, therefore, recognize early symptoms of AD 
for close monitoring.  
 Although important to recognize, an early diagnosis does not necessarily correlate 
with a longer lifespan or quality of life in those affected. Lifespans and death rates from 
AD remain difficult to categorize since patients often have a primary cause of death other 
than AD. The cause of death may be directly or indirectly related to the person’s 
cognitive decline and losses in activities of daily living (ADL). These include 
susceptibility to infection, depression, or muscle atrophy if a patient becomes bedridden. 
Estimates for 2016 predicted that over 700,000 people in the United States would die that 
year with AD1. Reporting standards still may not be capturing all AD-related deaths, 
particularly if a case was not diagnosed ante-mortem.   
 The prevalence of AD has grown rapidly over the past hundred years since Dr. 
Alois Alzheimer first described the disease in 1906. This is partly an artificial increase as 
more education on the disease has led to more screens in at-risk patients. The numbers of 
deaths from the disease have therefore risen because of the increase in people in the 
United States diagnosed with AD. In addition, since studies have shown a greater risk of 
developing AD with increasing age4, the rates of AD will continue to increase as life 
expectancies increase. In the 2016 statistics for the United States, 44 percent of those 
with AD were aged 75 to 84, and 37 percent were 85 or older1. The majority of people in 
the United States with AD are, therefore, above 75 years old due in part to longer life 
 3 
expectancies and better diagnostics.       
 With these rising rates of AD, it is imperative to understand how the disease state 
differs from typical aging patterns. According to the 2013 APA guidelines, a patient can 
receive an AD diagnosis if their symptoms involve a loss of one of the following: 
coherent speech, spoken or written language comprehension, object identification, basic 
motor skills, abstract thinking, or multi-command tasks. The presence of these symptoms 
must be medically verified and occur along with a memory decline and, critically, disrupt 
capable daily living5. These guidelines will help standardize diagnosis of AD by health 
care providers but must be complemented with a better understanding of underlying 
molecular mechanisms, disease markers, and diagnostic tools.  
Pathological Features of Alzheimer's disease  
 The APA guidelines are a useful but not complete criterion for an AD diagnosis. 
Medical imaging techniques have become more advanced, thereby increasing AD 
detection sensitivity. They are limited though because the disease is not isolated to a 
discrete part of the brain. Much is still not understood about the tissue atrophy seen in the 
brain in AD. Current research in the field has not come to a complete consensus about the 
sites of initial degeneration and whether the atrophy seen in different brain regions is 
connected or develops independently. What is known is that there are common patterns 
of atrophy in regions of the brain that include, with overlap; the limbic system, medial 
temporal lobe, frontal temporal lobe, and hippocampus (Figure 1).  
One confirmed pathology is that the atrophy seen throughout the brain originates 
from massive cell death of neurons, the primary cell of the nervous system (Figure 2). 
These neurons are responsible for signaling, cognition, and motor coordination. Neurons 
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have several defining features including the cell body, known as the soma, with multiple 
projections radiating off of the soma. These projections are differentiated into dendrites 
and axons. The dendrites are smaller and more numerous projections that receive the 
signals. The signaling is then propagated through the longer extensions known as axons. 
Most axons extend several microns away from the soma although, in extreme cases, 
axons can extend up to one meter. The range of dendrite compositions, axons, and their 
lengths correlates with the diversity of functions required by neurons found in both the 
central nervous system (CNS) and peripheral nervous system (PNS).  
Within these regions there are gray matter (GM) and white matter (WM) 
atrophies. The GM atrophies are from degeneration of the cell bodies or soma of central 
nervous system (CNS) neurons, while WM atrophies are degeneration of the CNS axons. 
Both atrophies are present in AD but it is not clear if the observed degenerations are 
connected, dependent, or entirely independent from each other6. Different studies have 
contradictory results with finding ranging from AD as a GM disease with WM atrophy a 
secondary effect to other studies showing no long-term connection3. Another hypothesis 
suggests that WM degeneration precedes GM atrophy7. The difference may be region 
specific as some correlation of GM and WM atrophy is seen in the hippocampus6 but 
there is little connection in the entorhinal cortex8. This field needs more study to 
understand the interplay between different brain regions and specific patterns of 
neurodegeneration present.     
 In addition to atrophies in different regions of the brain occurring in afflicted 
individuals, AD patients exhibit different levels of global neurodegeneration and 
reduction in brain volumes. The necrosis in AD is not entirely generalizable but some 
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common features have been observed. Globally there is an average 15% reduction of 
hippocampal volume per year in patients with AD compared to a 1.5% reduction in age-
correlated cognitively-normal individuals9. In addition, 80-90% of AD patients have 
medial temporal lobe atrophy (MTA) on both the hippocampus and entorhinal cortex 
(Figure 1)2.    
 While research in Alzheimer's disease has increased exponentially since the time 
of Dr. Alois Alzheimer and Dr. Emil Kraeplin in 1906, there is still relatively little 
understood about this devastating disease. The underlying causes of the 
neurodegeneration are multidimensional and it is not clear how changes on the molecular 
level translate into the observed neurodegeneration. Within neurons several molecular 
factors are implicated in AD, but not entirely understood. The transition from healthy 
neurons to diseased ones is unclear but understanding the molecular markers is important 
for early detection and identifying therapeutic targets.   
Tau is implicated in Alzheimer’s disease. 
The gross atrophies seen in the brain have a biochemical commonality as two 
macromolecules have been shown to aggregate in neurons of the medial temporal lobe 
(MTL). These molecules are thought to disrupt neuronal functions and lead to atrophy. 
With the advances in brain scan technology, several distinctive tangles and plaques have 
been found in patients diagnosed with AD. The tangles, known as neurofibrilary tangles 
(NFTs), are composed of the protein Tau and the plaques are composed of the amyloid-β 
protein fragment. The NFTs are found deposited in the MTL in the hippocampus and 
entorhinal cortex2. The pathological accumulation of these molecules contributes to the 
massive neuronal death seen in AD. Even though the exact roles of Tau and amyloid-β 
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are not well known, their pathological presence is well confirmed. 
The Tau protein is implicated in a broader range of diseases that are classified as 
Tauopathies. These diseases include AD as well as frontal temporal lobe dementia, some 
types of Parkinson’s disease, and Progressive supranuclear palsy. The Tau protein, which 
functions predominately in axons, is part of a class of microtubule associated proteins 
(MAPs)10. Tau has some known functions in the neurons but there is not much known 
about Tau’s dynamics or structure in the neuron and how this determines its functions or 
role in Tauopathies.  
Tau contains an N-terminal projection domain that contributes to its different 
proposed functions. 
Tau is a MAP found predominately in the axon associated with microtubules. It 
has a dynamic structure and does not have a known secondary structure11. The structure 
of Tau is important to understand in order to fully comprehend its functions in developed 
neurons. The N-terminus of Tau (Figure 3) is a projection domain that does not associate 
with the microtubule12, and is important for proposed functions of Tau. These include a 
role in signaling pathways and in microtubule dynamics and stability13 (Figure 4). 
Initial work showed that the N-terminus of Tau was important in determining 
microtubule spacing in microtubule bundles within the axon. Microtubules within 
bundles are closer to each other in the presence of Tau than with other MAPs or the 
absence of Tau. The N-termini of MAPs may interact with each other on adjacent 
microtubules to determine spacing as a function of their own length and reach. The in 
vitro study found that the microtubule spacing with Tau is consistent with spacing of 
microtubules in bundles found in actual axons14. Tau has a shorter N-terminal projection 
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domain than the MAPs found in dendrites, suggesting that microtubules in axon bundles 
are closer together than in dendrites.  
In addition, the N-terminal projection domain has been shown to facilitate cargo 
delivery in the axon. Previous work has additionally shown that a region of amino acids 
from 2-18, known as a phosphatase-activating domain (PAD), is the necessary and 
sufficient region for cargo delivery15. This PAD is found in all Tau molecules and 
different charges on the PAD have been shown recently to have effects on the dynamics 
of Tau16. 
The projection domain of Tau has additional effects on microtubule stability as 
displayed indirectly by N-terminal truncations. When the N-terminus is truncated in vitro, 
mimicking a species found pathologically in NFTs of AD brains, there is more Tau 
associated with tubulin. The truncated Tau is specifically associated more with acetylated 
tubulin and detyrosination tubulin. The detyrosinated tubulin species is a marker of 
microtubule stability since the PTMs occur on stable and long-lasting microtubules17. Tau 
is additionally known to interact with histone deacetylase 6 (HDAC6), the tubulin 
deacetylase, to prevent the deacetylase activity18. Although Tau plays an important role in 
HDAC6 activity, in vitro work with N-terminal truncations of Tau did not find an 
increase in activity of HDAC6 in those samples17. The proposed loss-of-function of Tau 
in inhibiting HDAC6 is potentially overcome by an increase in microtubules and stability 
in the presence of truncated Tau. To understand the contradiction of more acetylation in 
the presence of N-terminally truncated Tau, further work needs to determine if the 
increased tubulin modifications in the presence of N-terminally truncated Tau is the result 
of increased stability because Tau is more tightly bound without its N-terminus.  
 8 
The Tau protein has six isoforms with common domains between the isoforms. 
The gene locus for Tau on chromosome seventeen19 contains alternative splice 
sites resulting in six predominant isoforms (Figure 3). The primary structure of all Tau 
isoforms consists of an acidic N-terminus containing the PAD, two approximately central 
proline-rich regions, and C-terminal microtubule-binding repeats (MTBRs) (Figure 3). In 
the C-terminal region, isoforms of Tau either have 3 or 4 copies of a 31-amino acid 
microtubule-binding repeat insert. At the N-terminal region of the protein after the PAD, 
isoforms have 0, 1, or 2 copies of a 29-amino acid insert.  
The six isoforms are named 3RS, 3RM, 3RL, 4RS, 4RM, and 4RL; reflecting the 
combination of alternatively spliced inserts present in the protein. 3R versus 4R signifies 
the presence of three or four microtubule binding repeats, while S (zero), M (one), or L 
(two) refers to the number of acidic inserts in the N-terminal region of the molecule. The 
longest isoform, 4RL, therefore contains four C-terminal microtubule-binding domains 
and two N-terminal acidic inserts; while the shortest isoform, 3RS, contains three C-
terminal microtubule-binding domains and no N-terminal acidic inserts20. In the adult 
brain there is approximately a 1:1 expression of 3R to 4R isoforms21. 
Tau converts between diffusive and static states on the microtubule.  
Tau is a conformationally dynamic protein with no absolute secondary structure22. 
This lack of secondary structure allows flexibility within the protein. It binds reversibly 
with the microtubule through a combination of weak interactions in the MTBR, proline-
rich regions, and inter-repeat regions between MTBRs23. The structure of Tau and the 
presence of multiple isoforms, although not entirely understood, are thought to have 
unique and overlapping roles in modulating different functions of Tau within the axon.  
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Despite no definite secondary structure, Tau has a proposed dynamic equilibrium 
on the microtubule lattice switching between a static state and a diffusive state (Figure 5). 
The longest and shortest isoforms, 3RS and 4RL, have different dynamic equilibriums in 
in vitro studies. The 3RS isoform is found in the static state 62% of the time while 4RL is 
static 49% of the time24. In general, the shorter isoform is more static than the longest 
isoform. Previous to the research presented in this study, none of the other isoforms had 
been characterized.  
In single-molecule studies, 3RS has been found in the static state as individual 
molecules as well as multi-protein complexes of two to three molecules in a ratio of 1:4:2 
respectively. 4RL, however, prefers single molecule binding to two-molecule static 
complexes in a 3:1 ratio24. The function of the multi-Tau complexes is not well 
understood but there does not appear to be a significant number of molecules associated 
together in the diffusive state. 
Tau adopts some known features as it transitions into the disease state. 
In the disease state all isoforms of Tau are dissociated from the microtubule and 
prone to a pathological aggregation. The aggregates found in the disease state have 
accumulated modifications and are different from the physiological and reversible multi-
Tau complexes observed in single molecule studies. Pathologically Tau has been found 
hyperphosphorylated, truncated, and associated into paired helical filaments (PHFs). Tau 
is subjected to a caspase-3 and calpain cleavage at distinct sites creating several different 
sized truncations that are found alongside full-length molecules in the PHFs17,25.  The 
PHFs are the initial component to forming NFTs that are no longer bound to the 
microtubules and disrupt normal axon signaling26. In PHFs, Tau additionally has an 
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altered structure in the MTBRs that could contribute to aggregation27.  
Proposed models for the conversion of Tau from physiological aggregates into 
NFTs include stabilization of a bound state of Tau on the microtubule lattice24, post 
translational modification like misregulated phosphorylation28, mutations throughout the 
protein29, imbalance in the ratios between the isoforms expressed30, and other still 
developing ideas. Since studies have shown that mRNA levels of Tau are consistent 
between the healthy and disease states21, it does not appear that there is a change in the 
amount of Tau present causing aggregation and PHFs. Further work is needed to discern 
how microtubule binding is disrupted and the contribution of the different regions on 
aggregation.  
Pathologically Tau is proposed to disrupt axonal transport and communication 
through the axon. Studies have suggested that since the PHFs and subsequent NFTs of 
Tau are no longer bound to the microtubules they can disrupt normal axon signaling and 
stability with the axon26. Since Tau is thought to have multiple roles in the axon, it is 
difficult to chronicle the transition into the disease and Tau’s contribution.  
Alzheimer’s disease is known to have disruptions in axonal transport. 
Communication in a multicellular organism must be efficient yet accurate to 
integrate the activities of differentiated cells ranging from small organisms to 
coordinating the over two hundred distinct cell types in a human body. An organism must 
sense both external and internal stimuli and elicit fast responses ranging from pain to 
flight to hunger. Coordination of the senses occurs in the nervous system through its 
defining cell type, the neuron.  
 In order to maintain viable cell environments for signal propagation, neurons must 
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constantly exchange ion channels, synaptic proteins, pre-synaptic vesicles, organelles 
such as endosomes and mitochondria, plasma membrane components, and other 
molecules between the axon and soma31. Two prevalent mechanisms exist for exchanging 
molecules: simple diffusion and axonal transport32. Cytosolic, soluble proteins in 
particular move through the axoplasm with a combination of these methods based on the 
distance needed to travel and subcellular conditions34. Simple diffusion alone is not 
sufficient to distribute proteins and other components down the length of the axon. Active 
transport, therefore, is required for the mid- to long-range distance movement of cargo 
along the length of the axon in both directions. The mechanism of axonal active transport 
turns over elements of the axoplasm such as transporting the proteins that are primarily 
synthesized in the soma to the distal axon (anterograde transport) and taking molecules 
back to the soma for recycling (retrograde transport)33. In active transport motor proteins 
capable of hydrolyzing ATP, known as ATPases, transport cargo like proteins and 
organelles long distances along cytoskeletal filaments32.  
In axons there are three main cytoskeleton polymers including actin and 
neurofilaments, a type of intermediate filaments. The third type are microtubules and are 
the major tracks for motor protein movement35. Microtubules are dynamic polymers that 
provide structure and support for the axon as well as being tracks for motor proteins to 
move along. Microtubules are composed of heterodimers of α- and β-tubulin that 
associate and are added to both the plus-end of microtubules, the faster growing end 
extending away from the soma, and the negative-end which grows more slowly towards 
to soma. The tubulin heterodimers in a typical microtubule arrange into 13 protofilaments 
creating a structure approximately 25 nm in diameter. The microtubules polymerize most 
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rapidly during neurogenesis in the growth cone of developing neurons and in mature 
axons to develop short branch points off of stable microtubules populations. While the 
microtubules undergo dynamic instability during these times, most of the microtubules in 
the axon are strong, stable populations designated for structural support and as tracks for 
motor protein movement36. 
Within axons, different populations of stable microtubules can function in either a 
structural role or as a main road for motor proteins. Microtubules in a more structural role 
contain side extensions linking the microtubules to other cytoskeletal components like 
actin and neurofilaments. These projections could inhibit motor protein transport and 
axons have, therefore, evolved a separate population of microtubules for motor proteins 
to use for transport37. The preference of motor proteins for certain microtubules is also 
influenced by significant post-translational modifications (PTMs) on tubulin that 
modulate motor protein transport, the motors ability to associate with the microtubule38, 
and microtubule stability39. Tubulin is subjected to acetylation, polyglutamylation, 
phosphorylation, and other forms of modification, particularly on its C-terminal tail. The 
PTMs on tubulin’s C-terminal tail can influence the rate of motor protein transport as 
well as the propensity of motor proteins to bind the microtubule38. Along with MAPs and 
other proteins, these PTMs help regulate axonal transport and proper cargo delivery in the 
axon.  
Motor proteins such as kinesin transport cargo along microtubules.  
Along the microtubules, molecular motors walk carrying membrane-bound 
vesicles as their cargo. Members of the kinesin super family of motors (KIFs) are 
primarily responsible for the anterograde motion, transporting cargo away from the cell 
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body (Figure 6), while cytoplasmic dynein primarily performs the anterograde motion 
back towards the soma32. Dynein and some members of the kinesin family are processive, 
meaning the motors can take multiple steps on the tubulin dimers of the microtubule 
before dissociating. This processivity allows for greater run lengths along the microtubule 
at a sufficient rate for cargo delivery to maintain the axonal environment.   
The KIFs diversity of functions range from monomeric constructs to tetramers 
with four heads performing roles other than cargo transport40. Certain motors within this 
family are more attuned to carry particular cargos and navigate the motile environment 
more easily31. Kinesin motors also have specific CNS and PNS functions, although there 
is overlap between what cargos are carried by a particular kinesin and with how many 
different kinesin types a particular cargo can associate40. Typically adaptor proteins are 
involved linking KIFs or dynein with a designated cargo, increasing the combinations 
and specificity available for motor transport41.   
Multiple different motor proteins transport cargo in neurons and often multiple 
motors are associated with the same cargo forming multi-motor complexes. The presence 
of multiple motors on the same cargo is not entirely understood but is hypothesized to 
help the motors navigate a complex axon environment crowded with other motors, 
MAPs, actin, and additional factors42. In some cases there may be two oppositely-
directed motors on a cargo, such as dynein and kinesin. This is also hypothesized to 
ensure efficient cargo delivery as the dynein may engage causing the cargo to take a back 
step around an obstacle. The anterograde-transported vesicle can then continue forward 
as the kinesin motor has more space to find an available tubulin site43. Other cargos may 
have multiple different kinesin family members on the same cargo or a combination of 
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KIFs and dynein42,44. The combination of different motors increases how far the cargo 
travels on the crowded microtubule45.  
Kinesin-1 motor proteins walk along microtubules decorated with proteins and 
modifiers.  
One of the most commonly found and studied kinesin motors in axonal transport 
is kinesin-1. The kinesin-1 motor responsible for axonal transport contains two heavy 
chains, forming the motor domains responsible for microtubule-binding and ATPase 
activity, and two light chains able to bind membrane-bound vesicles and organelles32.  
The kinesin-1 motors typically step on the β-tubulin of the microtubule lattice at 
the interface between β-tubulin and the successive α-tubulin. The specificity for β-
tubulin lends kinesin-1 to take 8 nm steps per head in a 16 nm step cycle. In the absence 
of crowding, kinesin ATPase activity follows Michaelis-Menten kinetics at a velocity of 
600-800 nm/s, taking 12 ms per cycle at saturating ATP conditions.  
Kinesin-1 hydrolyzes a single ATP per step in an ATP-cycle. In the cycle (Figure 
6), the leading head is in the tightly bound state with no nucleotide in its binding site and 
the trailing head has a bound ATP that is hydrolyzed. With the subsequent phosphate 
release, the trailing head is in an ADP-bound state and has a weaker affinity for the 
tubulin. The head will unbind from the tubulin and, as an ATP binds to the pocket in the 
head that was initially the leading head, the neck linker docks and swings the trailing 
head forward to the next β-tubulin. At the end of the cycle, the now leading head has no 
nucleotide bound while the now trailing head has an ATP bound and is in a strong 
binding state, causing the cycle to start over46. The ATP cycle relies on the two heads 
being in different nucleotide states. This allows the motor to be processive because the 
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trailing head can swing forward to find the next tubulin while the leading head is in a 
strong-binding state.  
The longest and shortest isoforms of Tau can differentially modulate kinesin-1 
active transport in the axon. 
The MAP Tau is one such obstacle that has the ability to inhibit kinesin-1 axonal 
transport as it moves cargo towards the synapse47. Tau is proposed to inhibit kinesin-1 in 
order to regulate the arrival of vesicles at the pre-synaptic membrane (Figure 7). Under 
further study, 3RS and 4RL Tau cause kinesin-1 to pause or detach at different rates 
(Figure 7A). In the presence of 3RS, kinesin-1 has a 50% reduced run length and was 
more likely to detach than in the absence of Tau. Kinesin-1 in the presence of 4RL-Tau 
show no change in run length but had a higher frequency of detachment compared to 
microtubules without Tau47.  
The different rates of kinesin-1 transport correlate with research on the dynamic 
behavior of 3RS and 4RL isoforms on the microtubule surface (Figure 7A). Previous 
studies have found that 3RS is in the static state 62% of the time. 4RL-Tau is more 
dynamic and found in the static state 50% of the time. The differences in dynamic 
equilibrium suggest that 3RS is more inhibitory of kinesin-1 due to its longer static 
behavior. 
Tau has additional roles in axonal transport.  
In addition to modulating axonal transport, Tau is also involved in signaling 
cascades for the delivery of kinesin-1 cargo at distinct sites along the axon. The signaling 
cascade includes protein phosphatase 1 and GSK3β, a regulatory kinase. Truncations of 
Tau lacking either the MTBRs or MTBRs and C-terminus had a similar effects on cargo 
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deliver as full-length Tau by initiating the signaling cascade causing kinesin-1 to 
dissociate from its cargo48. These results suggest that the N-terminus of Tau is sufficient 
for inducing signaling cascades and regulation of axonal transport. 
 The signaling importance of Tau’s N-terminus has been further narrowed to a 
phosphatase-activating domain (PAD) in all six isoform of Tau from amino acids 2-1815. 
This PAD occurs before the start of the variable N-terminal acidic inserts. The PAD is 
sufficient and necessary to initiate signaling for cargo deliver by kinesin-115, but is not 
understood whether the presence of zero, one, or two acidic inserts has additional affects 
on this cargo-delivery signaling cascade. Recent work has shown differential modulation 
of kinesin-1 by the phosphorylation state of Tau. When the negative charge of a 
phosphate is present at Tyrosine-18, the last amino acid of the PAD; the Tau molecule is 
both more diffusive and less inhibitory of kinesin-116.   
Tau does not have a known structure on the microtubule. 
 Since there is no confirmed structure of Tau’s conformation on the microtubule, 
there is no clear understanding of how and why Tau transitions between the dynamic and 
static states. In addition, it is not clear how Tau interacts with the tubulin heterodimers of 
the microtubules. There are several cyro-EM studies suggesting that static Tau may lie on 
the microtubules across multiple protofilaments49, along a single protofilament50, or with 
density in between tubulin dimers51. Additional studies have also suggested that Tau 
binds at the interface between α-tubulin and β-tubulin52,53. Due to Tau’s dynamic nature 
and relatively quick transitions between static and diffusive states, however, the cryo-EM 
studies have low resolution and other studies have not provided a conclusive structure of 
static Tau.  
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 Despite a lack of convincing structure, there is strong evidence of how regions of 
Tau contribute to its binding on the microtubule. Individual Tau regions have weak 
microtubule binding capacities but with multiple regions interacting together, Tau has a 
strong microtubule binding affinity. Through NMR spectroscopy studies, Tau’s N-
terminus is found to have little interaction with the microtubule12. This is consistent with 
research suggesting that the N-terminus of Tau is a projection domain that extends away 
from the microtubule surface similar to those in other MAPs54. Other work has shown 
that C-terminal truncations of Tau are diffuse and do not associate cleanly with 
microtubules55, suggesting that the C-terminal MTBRs are necessary for microtubule-
binding. In addition, Tau constructs with the MTBRs removed additionally are found 
predominately in supernatant fractions in pelleting assays, indicating no detectable 
microtubule-binding56.  
Within 4RL-Tau there are six regions found to each have a weak binding affinity 
to the microtubule. There is one region within each PRR, one each in microtubule-
binding repeats one, two, and three; and one in the C-terminus of the protein. Together 
these six regions are shown in NMR to shift and adopt a different structure upon 
microtubule binding while other regions do not shift upon microtubule binding. The 
inter-repeat regions of Tau, for example, remain unbound and structurally unchanged 
upon microtubule binding, possibly contributing to Tau’s flexibility and reversible 
binding on the microtubule surface12. There is a similar shift seen in sequences in 3RS-
Tau with the exception of the region in the second MTBR as 3RS does not contain that 
repeat-domain52.  
Initial work on understanding regions within Tau found that the microtubule-
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repeat domains of Tau, but not the C-terminus or N-terminus alone, bound to 
microtubules in a pelleting assay. The pelleting assays further showed that when using 
artificially constructed microtubule-binding repeats, two repeats had a weaker affinity for 
microtubules than three repeats or even four repeats, which had the strongest affinity11. 
Along with the NMR work, these study are not entirely consistent with the kinesin-1 data 
or reported dynamic equilibriums of Tau where the 3RS, with one less microtubule 
binding repeat, spends more time in the static state on the microtubule than the isoform 
with four microtubule binding repeats24,47. 
N-terminal acidic inserts may have an effect on the dynamic equilibrium of Tau.  
Since the NMR work shows that more MTBRs alone correlates with a higher 
affinity for the microtubule, additional features of the Tau molecules must be 
contributing to its ability to switch between its static and diffusive states. One such 
component may be the presence of the N-terminal acidic inserts. Most of the previous 
research on Tau has compared the 3RS with 4RL isoforms. Despite the importance of the 
work, there are multiple differences between the molecules that limit the ability to 
attribute changes in Tau dynamics to any single region of the molecule (Figure 3). In 
particular, 3RS has three microtubule binding repeats and no N-terminal acidic inserts 
while 4RL has four microtubule inserts and two N-terminal acidic inserts21. It is, 
therefore, not possible to determine whether it is the N-terminal inserts or the MTBRs 
influencing the dynamics and functions of the Tau isoforms.  
It is important to understand differences caused by these acidic inserts because 
constructs with two inserts will likely have a longer projection above the microtubule that 
could possibly recruit more PP1 and GSK3β for cargo delivery and signaling. The acidic 
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inserts, however, may also change the equilibrium of static to diffusive Tau by stabilizing 
the diffusive state and reducing the time a Tau is static with its PAD exposed for 
signaling.  
Differences between the six isoforms of Tau needs to be better understood. 
The research performed here proposes to examine differences in the dynamic 
equilibrium of Tau by comparing Tau isoforms with different N-terminal acidic insert 
numbers but the same number of MTBRs. The results will contribute to understanding of 
how the N-terminal acidic inserts may change Tau’s equilibrium and, therefore, its ability 
to signal.  
The following study will examine the difference between acidic inserts within 3-
repeat Tau molecules. By keeping the microtubule-binding repeat numbers constant, this 
study will directly determine the role of the acidic inserts on Tau’s dynamic equilibrium 
on the microtubule surface. The research will compare 3RL, with two N-terminal acidic 
inserts, to 3RS, with no N-terminal acidic inserts. This study proposes that the N-terminal 
acidic inserts have an effect on the equilibrium of Tau on the microtubule surface. This 
study proposes that the isoform with two N-terminal acidic inserts will diffuse more often 
and for longer than the isoform without the inserts because the additional negative charge 
of the 3RL isoform is able to stabilize the dynamic state. 
Previous methods of data analysis may not have been sensitive enough to capture all 
events in single molecule assays. 
 The research presented here will examine the dynamic behavior of 3RS and 3RL. 
Previous research was able to compare the 3RS and 4RL isoforms but the methods used 
may not have been sensitive enough to capture short events or events that switched 
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between states (Figure 8). The initial work was completed by hand-selecting and 
characterizing events. In general, this means that very short events that were shorter than 
0.5 s were too difficult to objectively characterize as static or diffusive and were, 
therefore, discarded. Even with strict guidelines, some events were hard to confidently 
categorize by eye as diffusive or static and were, therefore, not included. Finally, any 
event that had both static and diffusive components, which is considered a switching 
event, was discarded.  
 The research presented here developed a novel data analysis to address the 
limitations of the previous methods. The research aims to take away the subjectivity of 
hand-picking and characterizing events. In addition, the data was analyzed by running the 
vectors of the events through a code designed specifically to be more sensitive to short 
events, objectively threshold which events where static or diffusive, and categorize 

















MATERIALS AND METHODS  
Plasmid Purification and Protein Prep 
 Tau constructs were purified from a modified pET vector, the ampicillin-resistant 
pET 3d, and transformed into BL21 competent cells (Aligent cat. 230255) that were 
pemeabilized on ice with βME (Bio-Rad cat. 161-0710). 2-5 ng of plasmid DNA was 
introduced to 100 µL of cells on ice and incubated for 30 minutes to allow the DNA to 
flow into the cells. The cells were heat pulsed for 30 seconds at 42°C then placed on ice 
for 2 minutes. Cells received 900 µL of S.O.C. recovery media (Invitrogen cat. 15544-
034, part 46-0821) and shook at 37°C, 225 rpm for 60 minutes. A range from 5-100 µL 
of cells were then plated on pre-warmed LB agar (Fisher Scientific BP 9724-500) plates 
with 50 µg/mL ampicillin salt (Sigma Aldrich A01566-5G) and incubated overnight at 
37°C. 
 After 16 hours plates were removed from the incubator and one colony was 
selected from a plate with sufficient growth to indicate a successful transformation, but 
without satellite colonies or overcrowding. The colony was place in 250 mL of LB (USB 
cat. 75852) with 0.1 mg/ml of ampicillin and rocked overnight at 37°C, 225 rpm. After 
16 hours, the cloudy sample indicated growth and 10 mL were taken into 1 L of LB-amp 
at 0.1 mg/mL. The culture shook at 37°C, 225 rpm until the OD measured at λ600 was 
0.6, approximately three hours. The culture was then induced with 0.5 mM IPTG  (Sigma 
cat. I6758-5G) and continued incubating for five hours. 
At the end of five hours, the 1 L culture was spun down in a Sorvall GS-3 rotor 
(Thermo Fisher Scientific, Waltham, MA) for 20 min at 6,500 rpm. The supernatant was 
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discarded and the pellet was saved at -80°C overnight. The pellet was thawed at room 
temperature for 45 minutes then lysed in 40 mL of lysis buffer (3.3mL 10X BRB80 [800 
mM PIPES pH 6.8 w/KOH, 10 mM EGTA, 10 mM MgSO4], 3.3mL 10X cellytic B, 10 
mM BME, 26.6mL ddH2O, 0.2 mg/mL lysozyme, 20 µg/mL leupeptin, 1 µg/mL 
Pepstatin A, 10 µg/ mL Aprotinin, 1 mM PMSF, 7500 U at 250 U/µl Benzonase) and 
homogenized on ice until the pellet was completely broken up and the solution was 
uniform. 
The solution containing the Tau protein was then sonicated on ice to break open 
the cells at a continuous pulse on for 30 seconds with 30 seconds or rest in between for 5-
7 times until the solution was clear. The solution was spun in a SA600 (Thermo Fisher 
Scientific, Waltham, MA) rotor for 20 minutes at 4°C at 15,000 rpm. The pellet was 
discarded and the supernatant was placed in boiling water for 20 minutes. Most of the 
proteins from the cell precipitated out and were spun down in the SA600 rotor for 20 
minutes at 4°C at 15,000 rpm. Tau was in the supernatant and was filtered through a 0.22 
µm filter. The salutation was then applied to a Q Sepharose Fast Flow column (Sigma 
cat. Q1126-100mL) at 4°C at a rate of 0.5-0.8 mL/min. The flow-through containing Tau 
was collected and stored overnight on ice at 4°C.  
The flow-through from the Q Sepharose column was applied to an SP Sepharose 
column (Sigma cat. S1799-100mL) at a rate of 0.5-0.8 mL/min. Tau sticks to the SP 
column so the flow-through was discarded. The column was then washed with BRB80 
until the OD read at λ280 was zero. Once the OD reached zero, 200 mM NaCl was 
applied to the column to elute the Tau off the column in 1 mL fractions. The OD λ280 
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was recorded for each third fraction to create an elution curve. Once the elution peaked 
and fell back closer to zero, the salt was increased to 1 M NaCl and several fractions were 
collected. 
Every other fraction was run on an SDS-PAGE gel and stained with Coomassie 
Blue stain (Figure 9A-B). Based on the samples on the gel, fractions containing Tau were 
pooled and placed in dialysis tubing 12-14 kDa MW cut off (Spectrum Labs cat. 132 678) 
and dialyzed in 2 L of 1x BRB80 overnight. After 16 hours, the dialysis tubing was 
placed in 1 L 1x BRB80 and dialyzed an additional 5 hours. The samples were aliquoted 
and flash frozen in liquid nitrogen to store long-term at -80°C. Tau concentrations were 
tested by a bicinchoninic acid assay (BCA assay) (Thermo Scientific prod. 23225) 
(Figure 9B).  
Tau labeling with Alexa 488.  
 Tau constructs were labeled with Alexa-488 (Life Technologies cat. A10254) that 
uses a cysteine-maleimide-fluor linkage system. Since the 3R-Tau only has one cysteine 
residue in microtubule-binding repeat three, the second MTBR present in the protein 
(Figure 3) the constructs were singly labeled. Tau was incubated at 10x its concentration 
of DTT for two hours at room temperature to reduce disulfide bonds in the protein. The 
sample was spun through Zeba desalting columns 7k molecular weight, 2 mL volume 
(Thermo Scientific cat. 89889) that had been equilibrated with 1 mL of 1x BRB80 three 
times. The flow-through was taken and incubated with 3x Alexa-488 10 mM in DMF for 
two hours in the dark at room temperature. Tau-488 samples were then spun through the 
same type of Zeba desalting columns equilibrated the same. The flow-through was 
collected and aliquoted for single molecule assays and flash frozen in liquid nitrogen for 
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long-term storage at -80°C. Samples were run on a polyacrylamide gel to ensure no non-
specific labeling occurred and that all excess dye had been filtered out (Figure 9C-D).  
 The concentration of Tau-488 constructs was determined by BCA assay (Figure 
9D). The efficiency of labeling was measured by !"#$%#&'(&)"#  !"  !"#$!    !"#$%#&'(&)"#  !"  !"#$%&' ∗ 100  where the 
concentration of label was determined by absorbance at λ493, the absorbance of the 
Alexa 488 dye, at different dilutions of the labeled protein. The concentration was then 
determined by the formula M = (OD/extinction coefficient )*dilution factor using the Alexa 488 
extinction coefficient. 
 In this study, the 3RS-Tau-488 construct stock concentration was at 92.28 µM 
and labeled with 49.6% efficiency. 3RL-Tau-488 stock concentration was at 23.33 µM 
and labeled at 97.8% efficiency.   
Diffusion Assay: Tubulin Polymerization. 
 Tubulin purified from calf brains underwent a clarification spin at 350,000 x g at 
4°C in a TLA 100 rotor in an ultracentrifuge for 20 minutes. The supernatant was 
removed and polymerized in the presence of 1 mM GTP at 37°C for 20 minutes. A 
sample of the supernatant was used to determine the OD at λ280 to find the tubulin 
concentration. The polymerized microtubules were stabilized with 20 µM paclitaxel and 
incubated at 37°C for at least 5 minutes.  
Diffusion Assay: TIRF Assay 
 The dynamic behavior of Tau was determined by a total internal reflection 
fluorescence assay (TIRF). Flow cells were constructed by adhering 0.005 mm plastic 
shims (Artus plastic shims, 0.005-0.125m/m) to silanized cover slips coated with PEG. 
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All solutions were diluted in a motility buffer (97% 1x BRB80, oxygen scavengers [3.5 
mg glucose, 27 ng catalase from bovine liver, 40 ng glucose oxidase from Aspergiuls 
niger], 10 mM DTT). A stock concentration of microtubules was incubated at 1:3000 
with the appropriate Tau construct at 37°C for 20 minutes. All reagents were prepared 
fresh for imaging that day. 
 For imaging, anti-β III tubulin was introduced to flow cells and incubated for 5 
minutes. Two washes of 0.5 mg/mL of BSA were flow-in to block spots without 
antibodies bound on the flow cells and allowed to bind for 2 minutes each. Between 1.2-
1.5 µM of microtubules, diluted from stock concentrations incubated with Tau, were then 
flowed in and incubated for 12 minutes. Tau was flowed in at a 1:3000 ratio of the 
microtubules, between 0.4-0.5 nM of Tau, and incubated for two minutes. 
 Slides were imaged with TIRF immediately on an inverted microscope (Eclipse 
Ti-U, Nikon) with a 100_ plan apochromatic objective lens (1.49 NA) and auxiliary 1.5_ 
magnification. Microtubules were first found and imaged with a 532 nm argon laser with 
an emission 605/70 band-pass filter. A 473 nm argon laser was then used to excite the 
Tau constructs with an emission 525/50 band-pass filter. The videos were captured by an 
XR/Turbo-Z camera (Stanford Photonics) with Piper Control software (v2.3.39) at a pixel 
resolution of 93 nm. On the microtubule field, 50 images were taken at 10 frames/second 
before immediately switching to image the Tau field for 1000 images at 10 
frames/second.  
Diffusion Assay: Data Analysis 
 Files from imaging were analyzed using ImageJ software,version 1.46r (National 
Institutes of Health, Bethesda, MD). Tau events were first confirmed by generating 
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kymographs, a two-dimensional representation of a movie, using the “multiple 
kymograph” plugin in ImageJ (Figure 8). Microtubule tracks were hand selected using 
the line tool and superimposed on the Tau fields to generate the kymographs (Figure 
10A). Actual events were tracked using the MTrackJ plugin. Tau molecules were hand 
selected and followed through successive frames using MTrackJ with a single frame step 
between points (Figure 10B-C).  
Data Analysis: MatLab 
 The spatial coordinates of the Tau events selected in the MTrackJ plugin were 
imported into MATLAB version R2016b (MathWorks, Natick, MA). A custom program 
was developed to distinguish between static and diffusive states for every event. The 
program calculated displacement of Tau particles at each time interval of 0.1 s, the frame 
rate during data collection, and the displacements were stored in a vector (Figure 10B-C). 
A sliding window analysis was performed on this displacement vector with a sliding 
window of size of 3 frames moving along the displacement vector.  
The maximum displacement was then calculated for each window. When the 
maximum displacement was less than 0.3 microns that region was classified as static and 
when the maximum displacement was greater than 0.3 microns that region was classified 
as diffusive. The threshold for a static versus diffusive molecule was based on the point 
spread function of the fluor and minimum amount of movement able to be detected. The 
size of the sliding window was optimized by analyzing simulated data. In this analysis, 
only those tau molecules that had a time interval greater than or equal to 0.4 s were used. 
From the sliding window analysis; the percentage of static and diffusive events, the 
percentage of transitions between states, and the time spent in each state was determined.  
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 To calculate the Diffusion Coefficient (D) and alpha value for diffusive events the 
mean squared displacements (MSD) were fit to the following equation (Figure 12):  
                          Equation 1                              x2 = 4Dtα                                                      
where x2 is the MSD and t is the time interval. MSD was first calculated for individual 
events using the following equation: 
Equation 2    𝑀𝑆𝐷 𝑗 =    (𝑑𝑖, 𝑖 + 𝑗)!!!!!!!!! 𝐿 − 𝑗 
Where j is the time interval, L is the number of values in the displacement vector and 𝑑𝑖, 𝑖 + 𝑗 is the displacement between time i and and  i + j. In this way MSD was 
calculated for each diffusive event. Then the MSD was averaged over all particles and fit 
to the diffusion equation to calculate D and the alpha value. The alpha value is the 
exponent of the time interval in Equation 1 and is a measure of the nature of the 
movement of a diffusive Tau event. It describes the nature of the line in the MSD versus 
time graph. If the alpha value is less than 1, the line is logarithmic and suggests a sub-
diffusive particle. If the value is equal to 1, the line will be linear and indicates a perfectly 
diffusive molecule. Finally if the value is 2, the line will be exponential and suggests 
directed motion.  
Data Analysis: Statistics 
 The lifetimes of the static and diffusive events were plotted on cumulative 
frequency plots using Graph Pad Prism version 7.0a (GraphPad Software, Inc. La Jolla, 
CA). The cumulative frequency plots were analyzed with a single exponential decay and 
the fit values, R2 values, were recorded as well as the dwell times, τ. The percentages of 
static and diffusive events were plotted as bar graph in Graph Pad Prism. Standard 
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deviations were calculated as: 
 Equation 3 standard deviation = √(p*q*100) 
The percentages were compared by a two-tailed Fisher’s exact test with a confidence 
interval of 95% through Graph Pad Prism. This statistical method allowed for comparison 
between the percentage of 3RS and 3RL events in the static versus diffusive states to 
determine statistical significance. The same process was repeated for the percentages of 
switching events to determine if there was statistical significance between the 3RS and 




Characterization of the 3RS and 3RL isoforms. 
The expressed 3RS and 3RL isoforms were first characterized for purity. In the 
protein preps, the predominant product is the Tau protein running near 37 kDa on the 
SDS-PAGE gel. As seen in a representative gel of fractions from column elution (Figure 
9A), the primary product is the 3RS protein that elutes cleanly in approximately 8-10 
fractions. The concentrations of 3RS and 3RL were determined by a BCA assay run 
against a known Tau standard (Figure 9B). The protein concentrations were then used to 
determine the amount of Alexa-488 needed to incubate the protein with the dye at a 3X 
concentration. The SDS-PAGE gels run after labeling were stained with Coommassie 
Blue after imaging fluorescence on a UV light box (Figures 9C-D). Again the 
predominant product that was labeled is the 37 kDa Tau protein. There is also not an 
excess amount of dye from the labeling process as seen on the SDS-PAGE gel. 
Concentrations were again determined by a BCA assay and the percentage of Alexa-488 
labeling was determined using the known extinction coefficient of the Alexa-488 dye. 
The resulting 3RS stock concentration was 92 µM, 49.6% labeled of which as labeled 
with Alexa-488. 3RL had a final concentration of 23 µM and was 97.8% labeled with 
Alexa-488.  
3RS and 3RL are found more often in the static state than the diffusive state. 
 In the single-molecule diffusion assays, 3RS dynamics were measured in four 
separate experiments and 3RL dynamics were measured in three separate experiments. In 
each experiment data was collected from 1-2 flow cells per day and a total, across all 
experiments, of 14 different Tau fields for 3RS and 20 different Tau fields for 3RL. Each 
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field had at least 100 Tau molecules imaged over 100 seconds at 10 frames/second. In 
total, 555 events of 3RS were analyzed and 2168 events of 3RL (Figure 11). 
The analysis showed that 3RS was in the static state 63% of the time and in the 
diffusive state 37% of the time. Similarly, 3RL was static 69% of the time and diffusive 
31% of the time. The percentages of static Tau were not statistically significant between 
the two isoforms with a P-value of 0.4556 at a 95% confidence interval of p < 0.05 
(Figures 11 and 13).  
3RS and 3RL have longer static dwell times than diffusive dwell times. 
Both 3RS and 3RL Tau had longer static dwell times than diffusive dwell times. 
Cumulative frequency plots were fit with a one-phase decay and the lifetime values were 
recorded as the dwell times (Figure 11). 3RS had a static dwell time of 0.53 s compared 
to its diffusive dwell time of 0.09 s. The static dwell time for 3RL at 0.55 s was six times 
longer than its diffusive dwell time at 0.12 s. The R2 values, indicating the fit of the one-
phase decay to the data, were as follows: 0.9806 for 3RS-static, 0.9816 for 3RL-static, 
0.9982 for 3RS-diffusive, and 0.9994 for 3RL-diffusive (Figure 11C).  
3R-Tau is more likely to switch from the diffusive state into the static state.  
 The novel data analysis developed here was sensitive enough to account for Tau 
events that switched from one state to the other. By using the sliding window analysis, 
the rates were determined for events that switched from the static to diffusive state and 
from diffusive to static state (Figures 12 and 13). Diffusive 3RS and 3RL constructs 
switched from diffusive to static 25% and 28% of the time, respectively. Comparatively, 
static 3RS molecules had a switching percentage from static to diffusive at a rate of 14%. 
3RL static molecules also switched from static to diffusive at a rate of 14% (Figures 12 
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and 13). These percentages were not statistically significant from each at a P-value of 
0.8198 at a 95% confidence interval of p < 0.05.  
3RS and 3RL Tau are diffusive with no directed motion.  
 The final parameters determined from the mean-squared displacement (MSD) 
analysis were diffusion coefficients and alpha values for 3RS and 3RL. The diffusion 
coefficients were 0.072 µm2/s for 3RS and 0.055 µm2/s for 3RL. The alpha values were 
determined by plotting the MSD over time. The lines were linear, indicating an alpha 
value near 1, indicative of purely diffusive molecules.  The alpha values were 0.970 for 
3RS and 1.055 for 3RL (Figure 14). 
3RS and 3RL have much shorter dwell times than previously reported. 
 Previous work had shown that 3RS is static 62% of the time with a static dwell 
times of 19.6 s and diffusive dwell times of 3.60 s (Figure 15)24. The current work found 
3RS was static 63% of the time with a static dwell time of 0.53 s and diffusive dwell time 
of 0.09 s. In order to understand the differences between the dwell times, the current data 
analysis was run again on the 3RS and 3RL data sets using the same thresholds as stated 
previously. Namely, any events less than 0.5 s (5 frames) were discarded. The results 
showed that the dwell times were not drastically changed (Figure 15). 3RS under the new 
parameters had a static dwell time of 0.63 s and a diffusive dwell time of 0.11 s. 3RL had 





3RS- and 3RL-Tau have similar dynamic equilibriums favoring the static state. 
 As shown in the results in Figures 11 and 13, both the 3RS and 3RL isoforms 
favor the static state at a 2:1 ratio. This is consistent with previous results using a 1:3000 
ratio of 3RS to tubulin where 3RS was found to be static 62% of the time24. This suggests 
that 3-repeat Tau isoforms overall favor the static state two-thirds of the time on the 
microtubule lattice.  
The dwell times of 3RS and 3RL similarly showed a preference for the static 
state. Both isoforms had a static dwell time around 0.5 s, five times their diffusive dwell 
times of approximately 0.1 s (Figures 11 and 13). These results also provide an insight 
into the length of time Tau may be on the microtubule to perform its various functions. In 
general, 3-repeat Tau molecules had short dwell times that indicate rapid turnover of the 
molecules on the microtubule surface. Previous work had found a similar relationship 
where 3RS spends five times as long in the static state as the diffusive with dwell times 
of 19.6 s to 3.60 s respectively24.  
The novel data analysis method was more sensitive and captured many more short 
events than previous methods. 
The analysis method used here was more sensitive and was able to characterize 
events that were not considered in the previous work (Figures 8 and 10). By using the 
sliding window analysis, a greater number of shorter events that were less than 0.5 s were 
captured. Events were also captured that either underwent a switching event or were not 
used previously because they were not clearly static or diffusive. Previous events were 
captured by hand-selecting Tau events directly from kymographs. In using kymographs, 
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very short events were not recorded and events were it was unclear if the molecule was 
diffusing were discarded.   
To make sure that the dramatic differences in dwell times was not an artifact of 
the novel data analysis used, the data was run through the analysis again using the same 
thresholds as previous published. This meant any event that was les than 0.5 s was 
discarded (Figure 15). The results showed that 3RS under the new parameters had a static 
dwell time of 0.63 s and a diffusive dwell time of 0.11 s. 3RL had a static dwell time of 
0.68 s and a diffusive dwell time of 0.13 s. These dwell times are still much shorter than 
previously reported, suggesting that the new data analysis method was indeed able to 
capture many events around 0.5 s that would not have been detected using previous 
methods of analysis. 
In general, many of the Tau events were close to 0.5 s. This suggests that many 
Tau events are relatively short. The previous data analysis characterized events by eye as 
either diffusive or static. As seen in Figure 8, even with strict parameters; this can be 
challenging because of noise in the data collection or because these events have motion 
but may not be enough to categorize as diffusive or static. This data analysis used the 
spatial coordinates of each event and used MATLAB codes to determine the amount the 
event moved between frames. The subjectivity, therefore, was eliminated and events that 
had noise could be clearly categorized.  
3R-Tau is more likely to switch from the diffusive state into the static state. 
Since this study used a novel analysis method, more information was captured 
including the rates of switching between static and diffusive events. Previously events 
like the one identified in the top kymograph of Figure 8, where a Tau switched between 
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states, were observed on kymographs but not quantitated. Again these results favor the 
static state for both 3RS and 3RL. Both constructs were approximately twice as likely to 
switch from the diffusive state to the static state than to begin diffusing while in the static 
state (Figure 12). 3RS and 3RL switched favored a switch from the diffusive to the static 
state 25% and 28% of the time, respectively. The 3R-Tau both switched from static to 
diffusive 14%.  
These results suggest that the 3-repeat Tau may be more stable in the static state 
or that it is an electrostatically more favorable conformation. In addition, the results may 
indicate that it is more favorable for the protein to shift from its conformation in the 
diffusive state into the static state. Since there is no known structure of Tau, more 
information is needed to understand why 3R-Tau favors the static state. A potential 
model for further study is that 3-repeat Tau lands on the microtubule and diffuses until it 
finds a suitable location. Since Tau has known signaling and other roles in the axons, it is 
possible Tau can land and search in the diffusive state for the appropriate location before 
binding. 
3RS and 3RL-Tau have similar dynamic equilibriums. 
 This study compared 3RS and 3RL isoforms that only differ in the number of N-
terminal acidic inserts. Since the percentages of static and diffusive events were not 
significantly different and the dwell times were comparable, these results suggest that 
there is no effect of the acidic inserts on Tau’s equilibrium. The presence of two 
additional acidic inserts in 3RL did not significantly change its behavior on the 
microtubule compared to the 3RS as expected. The N-terminal acidic inserts may, 
therefore, not have a role in the dynamics of Tau but have a greater effect on its signaling 
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or microtubule-spacing functions15,14.  
Tau is a purely diffusive molecule, with no directed motion or direction bias. 
 The diffusion coefficients of both 3RS and 3RL show that Tau is a diffusive 
molecule over distances with diffusion coefficients (D) of 0.072 µm2/s and 0.055 µm2/s, 
respectively (Figure 14). These D suggest that Tau is diffusing over a relatively large 
space each time. For comparison, the diameter of an average human microtubule is 20 
nm. Since the diffusion coefficients were 72 nm2/s and 55 nm2/s, this indicates a pretty 
diffusive molecule. These results are smaller than the previously reported diffusion 
coefficients of 3RS at 0.18 µm2/s24. Since the data reported here was more sensitive to 
shorter diffusive events, it is likely that the diffusion coefficient reflected more short 
events captured that had less time to diffuse.  
 The alpha values for the 3-repeat isoforms were also calculated at 0.97 for 3RS 
and 1.06 for 3RL (Figure 14). The alpha value is determined by plotting the MSD over 
time. As seen in Figure 14, the plot of the line is linear with R2 values of 0.9446 for 3RS 
and 0.9511 for 3RL, indicating a good fit to the line. The alpha values of 0.97 and 1.06 
respectively are close to the alpha value of 1 indicating a purely diffusive molecule with 
no directed motion. Taken together, the alpha values and diffusion coefficients suggest 











Evaluating Isoform Specific Differences 
 The results of this research show that there is not a significant difference in the 
dynamic behavior of the 3RS and 3RL isoforms of Tau on the microtubule lattice. The 
next step is to use the novel data analysis methods discussed here to assess the dynamics 
of the remaining four isoforms. Since 3RS and 3RL had statistically similar dynamics on 
the microtubule, the 3RM is proposed to also favor the static state at a 2:1 rate. 3RM is 
additionally expected to have longer static dwell times than diffusive dwell times and 
switch from the diffusive state into the static state twice as often as switching from static 
to diffusive states.  
 The 4-repeat isoforms of Tau will likely have different dynamics than the 3-repeat 
isoforms. Based on previous work comparing 3RS and 4RL dynamics24, the 4-repeat 
isoforms are proposed to have a 1:1 equilibrium between the static and diffusive state. 
The 4-repeat isoforms are proposed to similarly have longer diffusive dwell times than 
the 3-repeat Tau and shorter static dwell times. The individual 4-repeat isoforms are not 
expected to have statistically significant differences. These results would be similar to the 
3-repeat work discussed above where the N-terminal acidic inserts alone do not have an 
effect on the dynamic equilibrium of Tau. Since the 4-repeat isoforms have more 
microtubule-binding repeats to interact with the tubulin of the microtubule, it is necessary 
to evaluate the dynamics of those isoforms to know if there is any effect of the N-
terminal acidic inserts and to further understand why the 4RL isoform was more diffusive 
than 3RS in the previous work.  
Further work is needed to characterize 3R-Tau’s behavior on the microtubule. 
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Since 3-repeat Tau is known to form multi-Tau complexes24, it is possible that the 
static state was longer and more frequent because multi-Tau complexes were being 
observed. A brightness analysis was not performed as part of the experiments presented 
in the current work. This assay is necessary to run in the future determine if the events 
observed were single or multiple molecules. In addition, binding assay could be run to 
determine the affinity and cooperativity of Tau for binding on the microtubule.   
The analysis was stringent in the sense that any Tau event where a molecule 
became diffusive, static, or seemingly disappeared but the entire event still went on was 
discarded. For example, if a static Tau event was being measured through multiple 
frames and in one frame part of the molecule began diffusing away and the rest of the 
event was still static, it was assumed that there were actually at least two molecules being 
imaged and the entire event was not recorded. Further analysis is needed to determine the 
ability of 3RS and 3RL to form multi-Tau complexes and to look at the dwell times of 
complexes of Tau.  
Since the dwell times were similar in 3RS and 3RL, it is possible that they have 
the same numbers of multi-Tau complexes. The rates of multi-Tau complexes also need 
to be studied on the remaining four isoforms; 3RM, 4RS, 4RM, and 4RL. It would, 
furthermore, be important to see if some isoforms are more often found as multi-Tau 
complexes and how that effects their transition into the disease state.  
Isoform Differences on Kinesin-1 motility and signaling  
 Since there are not significantly differences between the 3RS and 3RL-Tau 
molecules, it would be interesting to look at known and proposed roles of Tau in axons to 
determine function-specific differences of these two isoforms. One such study would be 
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the motility of kinesin-1 in the presence of 3RS and 3RL to determine if the Tau isoforms 
inhibit kinesin-1 runs different in any significant manner. Since the dynamic equilibriums 
of 3RS and 3RL are similar, they may inhibit kinesin-1 similarly. Conversely, the 
additional acidic inserts in 3RL may impact the way the molecule interacts with kinesin-1 
and show very different inhibition of the motor protein. It would, therefore, be interesting 
to observe kinesin-1 in single molecule motility assays, similar to those performed 
before47,58, in the presence of 3RS or 3RL.  
 Further work could additionally look at differences in signaling between the 3RS 
and 3RL isoforms. The initial work on the phosphatase-activating domain of Tau used 
4RL-Tau15. It would, therefore, be interesting to see if the two added N-terminal inserts 
effect the signaling capabilities of Tau. The PAD is the region right before the acidic 
inserts begin. The presence of one or two acidic inserts could, therefore, project the PAD 
further above the microtubule and modulate the Tau’s ability to signal. These N-terminal 
acidic inserts may have an effect on recruiting kinases to initiate signaling for cargo 
delivery and other functions. One way to see the effect of the inserts on signaling would 
be to express different isoforms of Tau in cells and looks at the levels of phosphorylation 
on kinesin-1. This would indirectly show a change in signaling and recruitment of 







Since there were not any statistical differences in the dynamic equilibriums of 
3RS and 3RL, it is possible that there are functional differences based on the N-terminal 
acidic inserts. Further studies are needed to determine if the isoforms have 
complementary roles in signaling, microtubule spacing, and kinesin-1 inhibition. In 
addition, more work is needed to compare how all six constructs function and to begin 
understanding why there are six isoforms in the adult brain. Finally, these studies could 
be used to determine how Tau develops into the pathologies found in neurodegenerative 
diseases and potential therapeutic targets.  
The research described here is an important first step to answer many of these 
questions and to understanding the Tau protein. First, the novel data analysis tools 
developed here provided a more detailed and thorough characterization of the 3RS and 
3RL Tau proteins. These methods can be applied to other single molecule studies 
assessing the dynamics of Tau and other MAPs. Secondly, this study looked at two Tau 
isoforms that were previously not characterized relative to each other. By examining 3-
repeat isoforms, the work here begins to understand the role of the N-terminal acidic 
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